Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
|Articles|January 21, 2022
Daily OTC Pearl: Exederm
Author(s)Saro Arakelians, PharmD
Exederm treats itching, inflammation, redness, and rash associated with eczema and dermatitis.
Advertisement
Indication: Exederm is a flare control cream used for eczema and dermatitis.
Insight:
- Exederm contains 1% hydrocortisone anti-itch cream.
- Inactive Ingredients: Capric triglyceride, caprylic, caprylyl glycol, ceteareth-20, chamomile recutita flower extract, citric acid, glycerin, glyceryl stearate, palmitic acid, petrolatum, phenoxyethanol, stearic acid, and purified water.
- Avoid contact with the eyes.
- Do not begin use of any other hydrocortisone product unless directed by a physician.
- Exederm can relieve itching, inflammation, redness, and rash.
- Ultra-sensitive formula for highly sensitive skin.
- Fast acting when applied correctly.
Sources:
Advertisement
Related to this article
A helpful guide for pharmacists if teas, supplements, or cultural foods are part of a patient's regular routine.
Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
Pharmacy performance measures should recognize clinical interventions, patient counseling, prescriber collaboration, and outcomes—not prescription volume alone.
CMS’s GLP-1 Bridge demo bypasses Part D to cover select obesity drugs, with a $50 monthly copay, PA workflow, and strict eligibility through 2027.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
2
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
3
Cystatin C and the Future of Kidney Function Assessment
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5